Overweight or obese children and teenagers more likely to develop high BP as adults: Study

Blood pressure in adult men increased in a linear relationship with both higher childhood BMI (at age 8 years) and greater BMI change during puberty (BMI at 20 years minus childhood BMI), independent of each other, according to results of a Swedish population-based study.

In women, blood pressure in middle age increased in linear association with greater pubertal BMI change, but not childhood BMI.

“Our results suggest that preventing overweight and obesity beginning in childhood matters when it comes to achieving healthy blood pressure in later life”, says lead author Dr Lina Lilja from the University of Gothenburg in Sweden. “Children and teenagers living with overweight or obesity might benefit from targeted initiatives and lifestyle modifications to reduce the substantial disease burden associated with high blood pressure in later life from diseases such as heart attacks, strokes, and kidney damage.”

Children and teenagers living with overweight or obesity are more likely to have high blood pressure as adults (aged 50-64 years), suggesting the processes behind the condition could begin as early as childhood, suggests the new research being presented at this year’s European Congress on Obesity (ECO) in Venice, Italy (12-15 May).

Hypertension (persistent high blood pressure) is an important public health challenge worldwide because of its high prevalence and the associated risk of cardiovascular disease. WHO estimates that 1.28 billion adults aged 30-79 years are living with hypertension around the world . High blood pressure is the main cause of heart attacks, strokes, and chronic kidney disease, and is one of the most preventable and treatable causes of premature deaths worldwide. Modifiable risk factors include unhealthy diets, physical inactivity, and being overweight or obese.

A high BMI in adults is strongly associated with increased blood pressure and hypertension. However, the relative contribution of an elevated BMI during childhood and puberty to blood pressure in midlife is unknown.

To find out more, researchers analyzed data on 1,683 individuals (858 men and 825 women) born between 1948 and 1968 who were involved in two population-based cohorts-both the BMI Epidemiology Study Gothenburg (BEST) cohort and the Swedish CArdioPulmonary bioImage Study (SCAPIS)-to examine the association between BMI during development and systolic and diastolic blood pressure in midlife (50-64 years of age).

The researchers measured the developmental BMI of participants from the BEST Gothenburg cohort using school health care records (at the age of 7 to 8 years) and for young adult age (at age 18 to 20) from school health care or medical examinations on enrolment in the military which was mandatory for young men until 2010. Information on blood pressure in midlife (at age 50-64 years) was taken from participants in the SCAPIS study who were not on medication for high blood pressure at the time of blood pressure measurement. All analyses were adjusted for birth year.

The researchers used standard deviation, a commonly used statistical tool that shows what is within a normal range compared to the average.

In analyses including both childhood BMI and the pubertal BMI change in the same model, results showed that for men, an increase of one BMI unit from the average BMI in childhood (BMI 15.6kg/m2) was associated with a 1.30 mmHg increase in systolic blood pressure and a 0.75 mmHg increase in diastolic blood pressure, independent of each other.

Similarly, a one BMI unit increase from the average pubertal BMI (equivalent to an average pubertal BMI change of 5.4kg/m2) in men was associated with a 1.03 mmHg increase in systolic blood pressure and a 0.53 mmHg increase in diastolic blood pressure in middle age, independent of each other.

In women, a one BMI unit increase in pubertal BMI was associated with a 0.96 mmHg increase in systolic blood pressure and a 0.77 mmHg increase in diastolic blood pressure in middle age, irrespective of childhood BMI. In contrast, childhood BMI was not linked with systolic or diastolic blood pressure in midlife, irrespective of the pubertal BMI change.

“Although the differences in blood pressure are not very large, if blood pressure is slightly elevated over many years, it can damage blood vessels and lead to cardiovascular and kidney disease”, explains co-author Dr Jenny Kindblom from Sahlgrenska University Hospital i Sweden. “Our findings indicate that high blood pressure may originate in early life. Excessive fat mass induces chronic low-grade inflammation and endothelial dysfunction [impaired functioning of the lining of the blood vessels] already in childhood. Higher amounts of visceral abdominal fat increase the risk of developing hypertension in adults. We have previously shown that a large pubertal BMI change in men is associated with visceral obesity [fat around the internal organs] at a young adult age. So enlarged visceral fat mass might, in individuals with a high BMI increase during puberty, be a possible mechanism contributing to higher blood pressure.”

She adds, “This study is important given the rising tide of obesity among children and teens. We must turn the focus from high blood pressure in adults to include people in younger age groups.”

The authors note that the results are from observational findings, so more studies are needed to understand whether there are specific ages in childhood and/or adolescence when BMI is particularly important to blood pressure in adulthood. They also point to some limitations, including that a definite cause-and-effect link between BMI and high blood pressure cannot be determined in this type of population-based study; blood pressure was measured at a single point in time; the analyses were unable to account for the influence of other known risk factors such as diet and physical activity which could have influenced the results; and because most of the study participants were white, the results may not be generalizable to people from other racial or ethnic groups.

High blood pressure is defined as a systolic blood pressure (SBP) at or above 140mmHg or diastolic blood pressure (DBP) at or above 90mmHg.

Reference:

Study suggests high blood pressure could begin in childhood, European Association for the Study of Obesity, Meeting: European Congress on Obesity (ECO2024).

Powered by WPeMatico

Sleeping less than 6 hours daily may raise type 2 diabetes risk, regardless of healthy eating habits: JAMA

Sweden: A cohort study analyzing data from 247 867 adults in the UK Biobank revealed that adopting a healthy diet may not lower the risk of type 2 diabetes (T2D) development among those with habitual short sleep duration.

“Individuals getting sleep of less than 6 hours daily had a notably higher risk of T2D development versus those with 7 to 8 hours of sleep,” the researchers reported in their study published in JAMA Network Open. 

Despite the association between healthier diets and reduced risk of type 2 diabetes, the increased risk linked with short sleep duration persisted even among adults with healthy eating habits.

Previous studies have revealed substantial evidence of the adverse impact of short sleep duration on glucose metabolism. In contrast, current literature does not provide strong evidence that extended sleep in individuals with normal sleep patterns significantly disrupts glucose regulation. Thus, the association between habitual long sleep duration, often defined as more than 8 or 9 hours per day, and type 2 diabetes may not be causally linked.

Understanding the interplay between dietary habits, sleep duration, and the risk of T2D development is crucial for public health and diabetes prevention strategies. Considering this, Diana Aline Nôga, Department of Pharmaceutical Biosciences, Uppsala University, Sweden, and colleagues aimed to investigate the associations of type of diet and duration of sleep with type 2 diabetes development.

For this purpose, they analyzed data derived from the UK Biobank baseline investigation (2006-2010) between n May 1 and September 30, 2023. During a median follow-up of 12.5 years (end of follow-up, September 30, 2021), the association between sleep duration and healthy dietary patterns with the risk of T2D was investigated.

For the analysis, 247 867 participants were divided into four sleep duration groups: normal (7-8 hours per day), mild short (6 hours per day), moderate short (5 hours per day), and extreme short (3-4 hours per day). Their dietary habits were assessed based on population-specific consumption of processed meat, red meat, vegetables, fruits, and fish, resulting in a healthy diet score ranging from 0 (unhealthiest) to 5 (healthiest). The cohort comprised 247 867 participants with a mean age of 55.9 years; 52.3% were female.

Cox proportional hazards regression analysis was used to calculate hazard ratios (HRs) T2D development across various sleep duration groups and healthy diet scores.

The study led to the following findings:

  • During the follow-up, 3.2% of participants were diagnosed with type 2 diabetes based on hospital registry data.
  • Cox regression analysis, adjusted for confounding variables, indicated a significant increase in the risk of T2D among participants with 5 hours or less of daily sleep.
  • Individuals sleeping 5 hours per day exhibited a 1.16 adjusted HR, and individuals sleeping 3 to 4 hours per day exhibited a 1.41 adjusted HR compared with individuals with normal sleep duration.
  • Individuals with the healthiest dietary patterns had a reduced risk of T2D (HR, 0.75).
  • The association between short sleep duration and increased risk of T2D persisted even for individuals following a healthy diet, and there was no multiplicative interaction between sleep duration and healthy diet score.

In conclusion, the cohort study involving UK residents found that habitual short sleep duration is associated with an increased risk of developing type 2 diabetes. The association persisted even among those who maintained a healthy diet.

“To validate these findings, there is a need for further longitudinal studies, incorporating repeated measures of sleep (including objective assessments) and dietary habits,” the researchers wrote.

Reference:

Nôga DA, Meth EDMES, Pacheco AP, et al. Habitual Short Sleep Duration, Diet, and Development of Type 2 Diabetes in Adults. JAMA Netw Open. 2024;7(3):e241147. doi:10.1001/jamanetworkopen.2024.1147

Powered by WPeMatico

Monkeypox antibodies wane within year of vaccination, reveals study

New research to be presented at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) in Barcelona, Spain (27-30 April) shows that the antibodies produced by Modified Vaccinia virus Ankara – Bavarian Nordic (MVA-BN) vaccination against mpox wane significantly within a year of receiving the vaccination – but in people with pre-existing immunity due to childhood smallpox vaccination in childhood, antibody levels remain high in almost all cases. The study is presented by PhD student Dr. Marc Shamier, Erasmus MC, Rotterdam, Netherlands, from a research team led by Dr Rory de Vries.

During the 2022-2023 mpox outbreak, MVA-BN was rapidly deployed among at-risk populations, including gay, bisexual, and other men who have sex with men (GBMSM). This vaccine is based on a highly attenuated strain of Vaccinia virus (VACV) – a virus that belongs to the orthopoxvirus genus, as do the viruses that cause smallpox (variola virus) and Mpox (monkeypox virus).

Little is known about the longevity of immune responses induced by-MVA-BN vaccination and the impact of prior smallpox vaccination. In this study, the authors assessed the antibody levels response to MVA-BN one year after vaccination. While marketed under various names such as JYNNEOS, IMVANEX, and IMVAMUNE, all are brand names for the same Modified Vaccinia Ankara (MVA)-based vaccine. As such, the immunological effects they confer are expected to be consistent across these products.

Out of the 118 vaccine recipients, 36 (30%) returned for the 1-year follow-up visit. Among individuals without pre-existing immunity, 14/21 (67%) had undetectable levels of VACV IgG and a 10.7-fold decrease in VACV IgG GMT (geometric mean, a standard measurement for antibody levels) was observed compared to the last time point after vaccination in 2022 (4 weeks after the second dose) (Figure 1 full abstract).

In contrast, among individuals with childhood smallpox vaccination, only one participant out of 15 (7%) had undetectable VACV IgG after one year, and the GMT reduction between 4 weeks after the last vaccine dose in 2022 and the one-year follow-up visit was 2.5-fold for those vaccinated with two doses of MVA-BN, and 1.9-fold for those vaccinated with one dose of MVA-BN.

The authors say: “A rapid decline in VACV-specific IgG antibodies was observed one year after MVA-BN vaccination, leading to loss of detectable antibodies in 42% (15/36) of the participants. This reduction was most pronounced in individuals without pre-existing immunity. As the mechanism of protection for mpox remains undefined, the implications of waning antibody levels for conferring protection remain uncertain.”

The authors suggest that the decrease in antibodies over time following MVA-BN vaccination may be attributable its composition. They say: “The first and second-generation smallpox vaccines contained replication-competent vaccinia virus. MVA-BN is based on non-replicating virus, which may impact the strength and duration of the immune response; with the advantage of a low risk of side effects.”

They add: “Regarding the potential necessity for a booster, it is premature to draw such conclusions. It is unclear how waning antibody levels relate to protection. Immunity also involves other elements, such as T-cell responses. Comprehensive clinical monitoring over time, which connects infection rates with antibody levels, is required to make informed decisions about booster vaccination protocols.”

Reference:

Study shows Mpox (monkeypox) antibodies wane within a year of vaccination, European Society of Clinical Microbiology and Infectious Diseases, Meeting: The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024).

Powered by WPeMatico

Swapping meat and fish for mycoprotein may significantly lower cholesterol levels, finds study

Cardiovascular diseases (CVD) are highly prevalent and the leading cause of mortality from chronic, non-communicable diseases. Hyperglycaemia, hyperinsulinaemia, hypercholesterolaemia and high BMI are the risk factors for CVD.

A recent study published in Clinical Nutrition concluded that those who eat mycoprotein experience a 10% drop in certain cholesterol levels.
Proper nutrition relies heavily on a balanced diet, which includes protein from various sources. Researchers are exploring non-animal protein sources and their impact on cholesterol and blood sugar levels. Protein is an essential nutrient for the body’s systems. Mycoprotein, derived from a fungus, is used in some meat alternatives.
Laboratory-controlled studies have evidenced that Substituting dietary meat and fish for mycoprotein, a fungal-derived food source rich in protein and fibre, reduces circulating cholesterol. Researchers examined whether consuming mycoprotein-containing food products at home could impact cholesterol levels and other markers of cardiometabolic health in overweight and hypercholesterolaemic adults.
Seventy-two participants were randomized into a controlled, parallel-group trial conducted in a free-living setting. For four weeks, they received home deliveries of either meat/fish control products or mycoprotein-containing food products. Blood samples were collected and analyzed for serum lipids, blood glucose, and c-peptide concentrations before and after the intervention.
Key findings from the study are:
· Serum total cholesterol concentrations were unchanged throughout the intervention in the control group (CON) but decreased by 5 ± 2 % in MYC (mycoprotein group)
· Serum low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol concentrations were also unchanged in CON but decreased in MYC by 10 ± 3 % and 6 ± 2 %
· Serum high-density lipoprotein cholesterol and free triglyceride concentrations were unaffected in CON or MYC.
· Post-intervention, MYC displayed lower mean blood glucose and c-peptide concentration vs CON.
The study revealed that incorporating mycoprotein-rich foods into one’s diet can effectively reduce cholesterol levels in overweight, hypercholesterolemic adults. Consuming mycoprotein is a feasible and practical strategy to improve cardiometabolic health in at-risk individuals under free-living conditions. This strategy effectively reduces circulating cholesterol, blood glucose and c-peptide concentrations in adults at increased risk of cardiovascular disease.
Marlow Foods Ltd sponsored the study.
Reference:

Pavis, G. F., Iniesta, R., Roper, H., Theobald, H., Derbyshire, E., Finnigan, T. J., Stephens, F. B., & Wall, B. T. (2024). A four-week dietary intervention with mycoprotein-containing food products reduces serum cholesterol concentrations in community-dwelling, overweight adults: a randomised controlled trial. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2024.01.023

Powered by WPeMatico

SGLT2 Inhibitors Improve Skeletal Muscle Pathology in Heart Failure, reveals study

Patients with heart failure and reduced ejection fraction (HFrEF) often experience skeletal muscle pathology, contributing to symptoms and reduced quality of life. While sodium–glucose cotransporter 2 inhibitors (SGLT2i) have shown clinical benefits in HFrEF, their effects on skeletal muscle remain unclear. A recent study aimed to investigate whether SGLT2i influences skeletal muscle pathology in patients with HFrEF.

HFrEF patients commonly exhibit skeletal muscle abnormalities, exacerbating their condition. SGLT2i have emerged as promising treatments for HFrEF, yet their precise mechanisms of action are not fully understood. This study sought to elucidate the impact of SGLT2i on skeletal muscle health in HFrEF patients.

The study was published in the European Journal Of Heart Failure. The study was conducted by Nathanael Wood and colleagues. The study analyzed muscle biopsies from 28 male HFrEF patients treated with or without SGLT2i. Comprehensive analyses, including immunohistochemistry, transcriptomics, metabolomics, and serum inflammatory profiling, were conducted. Additionally, experiments in mice treated with SGLT2i were performed to validate findings.

The key findings of the study were:

  • Patients receiving SGLT2 inhibitors (SGLT2i) showed a significant reduction of approximately 20% in myofiber atrophy compared to untreated patients (p = 0.07).

  • Analysis revealed a distinct transcriptomic signature in SGLT2i-treated patients, associated with beneficial effects on muscle atrophy, metabolism, and inflammation.

  • Metabolomic profiling showed notable changes in tryptophan metabolism, with a 24% increase in kynurenic acid and a 32% decrease in kynurenine levels in SGLT2i-treated patients (p < 0.001).

  • SGLT2i treatment led to reduced levels of pro-inflammatory cytokines by 26–64%, alongside modulation of downstream muscle interleukin-6-JAK/STAT3 signaling (p < 0.05).

  • Experiments in mice treated with SGLT2 inhibitors demonstrated improvements in muscle pathology, supporting the clinical findings and indicating a conserved mammalian response to treatment.

The study suggests that treatment with SGLT2i influences skeletal muscle pathology in HFrEF patients, leading to anti-atrophic, anti-inflammatory, and pro-metabolic effects. These changes may be mediated through IL-6–kynurenine signaling. Improved skeletal muscle health may contribute to the clinical benefits of SGLT2i in HFrEF management.

The findings highlight the potential of SGLT2i as therapeutic agents not only for cardiac outcomes but also for improving skeletal muscle health in HFrEF patients. Further research is warranted to optimize treatment protocols and better understand the underlying mechanisms.

Reference:

Wood, N., Straw, S., Cheng, C. W., Hirata, Y., Pereira, M. G., Gallagher, H., Egginton, S., Ogawa, W., Wheatcroft, S. B., Witte, K. K., Roberts, L. D., & Bowen, T. S. (2024). Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3192

Powered by WPeMatico

AIIMS INI SS July 2024: Here are feeder qualifications

New Delhi- All India Institute of Medical Sciences (AIIMS) invited online applications for the Institute of National Importance Super-Specialty Entrance Test (INI-SS) for admission to DM, MCh and MD (Hospital Administration) courses at AIIMS, PGIMER, NIMHANS, SCTIMST and JIPMER for July 2024 session. In its prospectus, the AIIMS detailed the eligibility criteria/ feeder qualifications for candidates. 

The registration process has already begun and the last date for online registration of applications on the AIIMS website is Wednesday, 10th April 2024 till 5:00 PM. The course will resume from 01 July 2024. 

INI-SS for July 2024 session is planned to be held in 16 cities in India such as Ahmedabad, Puducherry, Bhopal, Bhopal.

Also Read: AIIMS INI SS July 2024 registrations begin, apply now

ONLINE REGISTRATION FOR APPLICATION

Status of Application & Rejected application with reason for rejection. Applicants are required to check their status through the Registration Status of My Page after Login.

13.04.2024

Saturday

Last date for submission of required documents for Regularisation of Rejected Applications. No Correspondence will be entertained after the given date under any circumstances and candidates are requested NOT TO CONTACT the Examination Section.

16.04.2024

Tuesday

Last date for Ministry of Health & Family Welfare, Govt. of India to forward an approval regarding “No Objection” to the Foreign National. Sponsorship certificates duly signed by competent authority for candidates applying under Sponsored seats should also be reached at the Examination Section.

16.04.2024

Tuesday

Submission of Certificate for Scribe and/or Compensatory time as applicable (Performa A-1/A-2/ A-3 of Appendix A)

17.04.2024

21.04.2024

Finalization of Centers and allotment of Roll No’s/Admit Card on the website

22.04.2024

Monday

Written Test through online (CBT) mode

27.04.2024

Saturday

Last date for fulfilment of Eligibility for admission

31.07.2024

Last date for admission to the course

31.08.2024

Expected date of declaration of Result (for all INIs)

To be announced

Expected date of declaration of Result(Stage-I) only for AIIMS applicant

To be announced

Departmental Assessment (Only for AIIMS applicants)

To be announced

Final Result

To be announced

DM COURSES ELIGIBILITY

S.NO

COURSE

ELIGIBILITY

1

ACUTE CARE-EMERGENCY MEDICINE

MD Internal Medicine/General Medicine/ Emergency Medicine or Equivalent

2

ADDICTION PSYCHIATRY

M.D./DNB in Psychiatry of this Institute or any other University or equivalent degree recognized by the NMC

3

CARDIAC SURGICAL INTENSIVE CARE

MD/DNB in Anaesthesia/Paediatrics/Medicine of this Institute or any other University or equivalent degree recognized by the NMC

4

CARDIAC-ANAESTHESIOLOGY/DM-CARDIOTHORACIC & VASCULAR ANESTHESIA*/Cardiac Anaesthesia & Intensive Care

M.D/ DNB in Anesthesiology of this Institute or any other University or equivalent degree recognized by the NMC

5

CARDIOLOGY

M.D/DNB in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

M.D/DNB in General Medicine/Paediatrics of any Indian University or equivalent degree recognized by the NMC

MD in Medicine or equivalent

M.D/ DNB Degree in General Medicine / Paediatrics/ Pulmonary Medicine recognized by the NMC

6

CARDIOVASCULAR RADIOLOGY & ENDOVASCULAR INTERVENTIONS/DM-CARDIOVASCULAR IMAGING AND VASCULAR INTERVENTIONAL RADIOLOGY

M.D /DNB in Radio-Diagnosis or equivalent degree

M.D /DNB in Radio-Diagnosis/Radiology of any Indian University or equivalent degree recognized by the NMC

7

CHILD AND ADOLESCENT PSYCHIATRY

MD/DNB Psychiatry or equivalent

8

CLINICAL HEMATOLOGY

M.D/ DNB in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

MD Medicine or equivalent

9

CLINICAL IMMUNOLOGY & RHEUMATOLOGY

MD Medicine, MD Paediatrics

MD Medicine or equivalent

MD/DNB General Medicine/Paediatrics

10

CLINICAL PHARMACOLOGY

M.D. in Anaesthesiology/Medicine/Chest Medicine of this Institute or any other University or equivalent degree recognized by the NMC

M.D. in Anaesthesiology/ General Medicine/Pulmonary Medicine of this Institute or any other University or equivalent degree recognized by the NMC

MD Anaesthesia/Internal Medicine or equivalent

11

ENDOCRINOLOGY

M.D./ DNB Degree in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

M.D./ DNB Degree in General Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

MD Medicine or equivalent

12

FORENSIC PATHOLOGY

MD/DNB Forensic Medicine/Forensic Medicine and Toxicology recognized by Medical Council of India/NMC

13

FORENSIC PSYCHIATRY

MD/DNB in Psychiatry

14

FORENSIC RADIOLOGY & VIRTUAL AUTOPSY

MD/DNB Forensic Medicine/Forensic Medicine and Toxicology recognized by Medical Council of India/NMC

15

GASTROENTEROLOGY/MEDICAL GASTROENTEROLOGY

M.D/ DNB in Medicine of this Institute or any other University or equivalent degree recognized by the NMC

MD Medicine or equivalent

M.D/ DNB in General Medicine /Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

16

GERIATRIC PSYCHIATRY

MD/DNB in Psychiatry

17

HEMATOPATHOLOGY

M.D/DNB in Pathology/Lab. Medicine of this Institute or any other University or equivalent degree recognized by the NMC

MD Pathology or equivalent

18

HEPATOLOGY

MD Medicine/Paediatrics or equivalent

19

HIGH ALTITUDE MEDICINE

MD/DNB Internal Medicine/Physiology/Anaesthesia/Community Medicine recognized by the Medical Council of India

20

HISTOPATHOLOGY

MD Pathology or equivalent

21

HOSPITAL MEDICINE & CRITICAL CARE

MD in Internal Medicine, Geriatric Medicine

22

INFECTIOUS DISEASES/ CLINICAL INFECTIOUS DISEASES

M.D/DNB in Medicine/Paediatrics/Microbiology/Tropical Medicine of this Institute or any other University or equivalent degree recognized by the NMC

M.D/DNB in General Medicine/Paediatrics /Tropical Medicine of this Institute or any other University or equivalent degree recognized by the NMC

MS/DNB is internal/General medicine

23

INTERVENTIONAL RADIOLOGY

MD/DNB (Radiology/Radio-diagnosis) recognized by MCI/NMC

MD/DNB in Radio-diagnosis or equivalent

24

MEDICAL AND FORENSIC TOXICOLOGY

MD/DNB In forensic Medicine or forensic Medicine &Toxicology/Pharmacology/Emergency Medicine/Internal/General Medicine/Paediatrics recognized by the Medical Council of India/ NMC

25

MEDICAL GENETICS

MD in Paediatrics/Medicine/Obstetrics and Gynaecology of this Institute or any other University or equivalent degree recognized by the NMC

MD Paediatrics or equivalent

26

MEDICAL ONCOLOGY

M.D/DNB in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

M.D. / DNB Degree in Medicine / Pediatrics /Radiotherapy recognized by the Medical Council of India

27

NEONATOLOGY

M.D Degree in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

28

NEPHROLOGY

M.D/DNB in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

M.D/DNB in General Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

MD in Medicine or equivalent

29

NEURO-ANAESTHESIOLOGY & CRITICAL CARE/DM-NEURO ANAESTHESIA*/NEUROANAESTHESIA AND NEUROCRITICAL CARE

M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC

30

NEUROIMAGING AND INTERVENTIONAL NEURORADIOLOGY/NEUROIMAGING AND INTERVENTIONS

M.D./ DNB Degree in Radio diagnosis of this Institute or any other University or equivalent degree recognized by the NMC

M.D./DNB in Radiology or equivalent

M.D./ DNB Degree in Radio diagnosis/Radiology of any Indian university or equivalent degree recognized by the NMC

31

NEUROLOGY

M.D. in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

M.D. in General Medicine/Paediatrics of an

M.D./DNB in Internal (General) Medicine/Paediatrics

MD in Medicine or equivalent

32

NEUROPATHOLOGY

MD/DNB in Pathology

33

ONCO-ANAESTHESIA

M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC

34

PAEDIATRIC ANAESTHESIA & INTENSIVE CARE

MD Anaesthesia or equivalent

35

PAEDIATRIC CARDIOLOGY

M.D.in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

36

PAEDIATRIC CLINICAL IMMUNOLOGY AND RHEUMATOLOGY

MD Paediatrics or equivalent

37

PAEDIATRIC EMERGENCY MEDICINE

MD/DNB Paediatrics or Emergency Medicine recognized by Medical Council of India/NMC

38

PAEDIATRIC ENDOCRINOLOGY

MD Paediatrics or equivalent

39

PAEDIATRIC GASTROENTEROLOGY & HEPATOLOGY/PAEDIATRIC GASTROENTEROLOGY

MD/DNB Paediatrics or equivalent

40

PAEDIATRIC HAEMATOLOGY-ONCOLOGY

MD/DNB Paediatrics or equivalent

41

PAEDIATRIC NEPHROLOGY

M.D/DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

42

PAEDIATRIC NEUROLOGY

M.D/ DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

43

PAEDIATRIC ONCOLOGY

M.D.in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

44

PAEDIATRIC PULMONOLOGY & INTENSIVE CARE

M.D.in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC

45

PAEDIATRIC PULMONOLOGY

MD Paediatrics or equivalent

46

PAEDIATRICS CRITICAL CARE

MD/DNB Degree in Paediatrics or equivalent

47

PAIN MEDICINE

MD(Anaesthesiology) or equivalent

48

PULMONARY CRITICAL CARE & SLEEP MEDICINE

M.D in Medicine/MD Pulmonary Medicine/MD Chest Medicine/MD Respiratory Medicine of this Institute or any other University or equivalent degree recognized by the NMC

MD Medicine/Respiratory Diseases or equivalent

49

REPRODUCTIVE MEDICINE

MD/MS in Obstetrics and Gynaecology of this Institute or any other University or equivalent degree recognized by the NMC

50

THERAPEUTIC NUCLEAR MEDICINE

M.D in Nuclear Medicine of this Institute or any other University or equivalent degree recognized by the NMC

51

TRAUMA ANAESTHESIA & ACUTE CARE

MD Anaesthesia or equivalent

52

PAEDIATRIC ANAESTHESIOLOGY

MD Anaesthesiology

53

VIROLOGY

MD Microbiology

Also Read: AIIMS INI SS July 2024 – Check Out Scheme Of Examination

MCh COURSES ELIGIBILITY

S.NO

COURSE

ELIGIBILITY

1

BREAST, ENDOCRINE AND GENERAL SURGERY

M.S. degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

MS (Surgery/General Surgery/equivalent)

2

C.T.V.S/CVTS

M.S./DNB degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

3

CORNEA, CATARACT AND REFRACTIVE SURGERY

MD/MS Ophthalmology or equivalent

4

GYNAECOLOGIC ONCOLOGY

MD/MS in Obstetrics & Gynaecology of this Institute or any other University or equivalent degree recognized by MCI

5

HAND AND MICROVASCULAR SURGERY

M.S degree in General Surgery/Orthopaedics of this Institute or any other University or any other equivalent degree recognized by the NMC/MCI

6

HEAD-NECK SURGERY AND ONCOLOGY / HEAD & NECK SURGERY

M.S degree in Surgery/ENT of this Institute or any other University or any other equivalent degree recognized by the MCI

7

JOINT REPLACEMENT & RECONSTRUCTION

MS/DNB Orthopaedics or an equivalent degree recognized by the Medical Council of India/NMC

8

MINIMAL ACCESS SURGERY & GENERAL SURGERY

M.S. degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

9

NEURO-SURGERY

M.S./DNB degree in Surgery of this Institute or any other University or (II) PGIMER any other equivalent degree recognized by the MCI

M.S./DNB degree in General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

10

PAEDIATRIC ORTHOPEDICS SURGERY/ PAEDIATRIC ORTHOPEDICS

MS/DNB Orthopaedics or equivalent

11

PAEDIATRIC SURGERY

M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

12

PLASTIC AND RECONSTRUCTIVE SURGERY/PLASTIC SURGERY

M.S degree in Surgery/ENT/Orthopaedics of this Institute or any other University or any other equivalent degree recognized by the MCI

M.S /DNB degree in General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

13

RENAL TRANSPLANT SURGERY

MS Surgery or equivalent

14

SPINE SURGERY

MS/DNB Orthopaedics or an equivalent

15

SURGICAL ONCOLOGY

M.S degree in Surgery/ENT of this Institute or any other University or any other equivalent degree recognized by the MCI

M.S./ DNB Degree in General Surgery / Obstetrics & Gynaecology / Otorhinolaryngology (E.N.T) / Orthopaedics Surgery recognized by the MCI

16

TRAUMA SURGERY AND CRITICAL CARE

M.S degree in Surgery/Trauma and Emergency Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

17

UROLOGY

M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI

18

VITREORETINAL SURGERY

MD/MS Ophthalmology or equivalent

MD (HOSPITAL ADMINISTRATION) ELIGIBILITY

1 The candidate must possess an MBBS or an equivalent degree (As per NMC).

2 Must possess a minimum experience of three years in a Govt. Hospital in the relevant field or five years in general practice. A certificate issued by the District Magistrate in support of the general practice claimed should be uploaded.

3 Candidates belonging to UR/OBC/EWS/Sponsored must have obtained 55% in aggregate in all MBBS Professional Examinations. Candidates belonging to SC/ST must have obtained a minimum of 50% marks in aggregate in all MBBS professionals.

4 Must be registered with the Central /State Medical Registration Council.

5 The candidates who have already done MD/MS or equivalent are not eligible for this course.

Along with this, Indian National candidates who have been graduated from foreign Universities must fill their NMC screening exam marks in percentage in the online form. Candidate must have obtained marks as mentioned above in FMGE exam conducted by NBE or any other authority of Govt. of India, Delhi will also be considered eligible.

To view the prospectus, click the link below

https://medicaldialogues.in/pdf_upload/iniss-final-prospectus-july-2024-235316.pdf

Powered by WPeMatico

Can Corporate Hospitals Advertise? NMC Panel Reaches Consensus, to submit its report to Supreme Court

New Delhi: The National Medical Commission’s (NMC) panel, which was formed based on the Supreme Court’s directions to examine the issue of advertising by corporate hospitals, is going to submit its recommendations to the Supreme Court.

Reaching a consensus, the NMC panel has opined that the rules of advertisement shall be the same for the corporate hospitals as well as for the doctors and other health facilities, The Print has reported.

Endorsing the rules suggested last year in the National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2023, the panel has expressed its opinion that only “ethical” advertisements by corporate hospitals should be allowed.

The NMC panel was formed after a Public Interest Litigation (PIL) was filed before the Supreme Court by Dr. Aniruddha Malpani, who highlighted that even though private medical practitioners are barred from advertising, such a restriction does not apply to corporate hospitals.

Medical Dialogues had earlier reported that by filing the PIL, Dr. Malpani had sought directions to frame comprehensive guidelines to be followed by the Corporate Hospitals, to ensure safe and ethical advertising and to have a holistic solution to the problem of illegal advertising. Further, the plea also sought to prevent indirect branch of the statutory regulations by doctors affiliated with Corporate Hospitals.

Also Read: Should there be rules to govern advertisements by Corporate Hospitals? NMC forms panel to decide

Based on the Apex Court’s directions, an NMC panel was formed and the Apex Medical Commission decided that the panel would examine whether there should be specific rules to govern advertisement by corporate hospitals.

What the NMC Panel has Suggested?

The Print has reported that the seven-member NMC panel has reached a consensus that the ethical norms related to advertisements applicable to doctors should be extended to the hospitals, including the corporate hospitals. Last month, the panel held a meeting and the minutes of the meeting stated that since the Code of Ethics Regulations 2002 refers to the medical profession and not medical professionals, NMC can prescribe rules of advertising for the hospitals as well.

“Section 10.1.(h) of the Indian Medical Council (Professional Conduct, Etiquette And Ethics) Regulations, 2002 clearly says that ‘…laid down policies and code to ensure observance of professional ethics in medical profession…’ and not by medical professionals, which clearly means that NMC can interfere in the hospitals also,” stated the minutes of the meeting.

“So, it can be safely said that the committee (NMC panel) can make regulations in this matter if the Hon’ble Court thinks it is required,” the NMC panel further observed in this regard.

Further, the minutes of the meeting further stated that the NMC panel members have suggested that the guidelines should be issued for “unethical” advertisements by corporate hospitals but “they should not differ from the already existing professional conduct content, which are already in abeyance.”

In this regard, NMC member and chairman of the NMC Panel, Dr. Yogender Malik informed The Print that the panel was in the process of preparing a report based on the suggestions made by its members. Following this, the report will be submitted to the Supreme Court.

Also Read: Breaking News: NMC puts its controversial Registered Medical Practitioner (Professional Conduct) Regulations, 2023 on hold

Can Doctors Advertise? 

The issue of advertising by doctors and hospitals had been addressed in the Code of Medical Ethics, 2002 as well as the NMC RMP (Professional Conduct) Regulations, 2023, which were later withdrawn by the Commission.

Addressing the issue of advertising, the Indian Medical Council (Professional conduct, Etiquette and Ethics) Regulations, 2002 stated the following:

“6.1 Advertising:

6.1.1 Soliciting of patients directly or indirectly, by a physician, by a group of physicians or by institutions or organisations is unethical. A physician shall not make use of him / her (or his / her name) as subject of any form or manner of advertising or publicity through any mode either alone or in conjunction with others which is of such a character as to invite attention to him or to his professional position, skill, qualification, achievements, attainments, specialities, appointments, associations, affiliations or honours and/or of such character as would ordinarily result in his self aggrandizement. A physician shall not give to any person, whether for compensation or otherwise, any approval, recommendation, endorsement, certificate, report or statement with respect of any drug, medicine, nostrum remedy, surgical, or therapeutic article, apparatus or appliance or any commercial product or article with respect of any property, quality or use thereof or any test, demonstration or trial thereof, for use in connection with his name, signature, or photograph in any form or manner of advertising through any mode nor shall he boast of cases, operations, cures or remedies or permit the publication of report thereof through any mode. A medical practitioner is however permitted to make a formal announcement in press regarding the following:

  1. On starting practice.
  2. On change of type of practice.
  3. On changing address.
  4. On temporary absence from duty.
  5. On resumption of another practice.
  6. On succeeding to another practice.
  7. Public declaration of charges.

6.1.2 Printing of self photograph, or any such material of publicity in the letter head or on sign board of the consulting room or any such clinical establishment shall be regarded as acts of self advertisement and unethical conduct on the part of the physician. However, printing of sketches, diagrams, picture of human system shall not be treated as unethical.”

What was recommended in NMC RMP (Professional Conduct) Regulations 2023? 

The rules regarding the nature of advertisements by corporate hospitals had also been addressed in the NMC RMP (Professional Conduct) Regulations, 2023, which NMC later withdrew.

These regulations allowed “ethical” advertisements by both individual doctors and health facilities. Section 11 of the regulations dealt with the issue of Advertisement and it stated the following:

11. Advertisement:

A. RMP is permitted to make a formal announcement in any media (print, electronic or social) within 3 months regarding the following: (1) On starting practice (2) On change of type of practice (3) On changing address (4) On temporary absence from duty (5) On resumption of practice (6) On succeeding to another practice (7) Public declaration of charges. (L2).

B. RMP or any other person including corporate hospitals, running a maternity home, nursing home, private hospital, rehabilitation center, or any type of medical training institution, etc. may place announcements in the print, electronic and social media, but these should not contain anything more than the name of the institution, type of patients treated or admitted, kind of doctors and staff training and other facilities offered and the fees. (Guidelines on social media conduct) (L1 and/or L2)

C. RMP is allowed to do public education through media without soliciting patients for himself or the institution (L2)

Also Read: How to regulate advertisements by corporate hospitals? Supreme Court asks NMC, Centre

Powered by WPeMatico

CDSCO Drug Alert: 58 Drug Samples Including Alkems’s Pyricool 500, Glenmark’s Deferasirox, Sun Pharma’s Zole F Flagged

New Delhi: In its latest drug safety alert, the apex drug regulatory body, the Central Standard Control Organisation (CDSCO) has flagged 58 medicine batches for failing to qualify for a random sample test for February 2023, while 2 drug samples have been declared as suprious.

These drugs include Acepik – P (Aceclofenac and Paracetamol Tablets) manufactured by Nexkem Biotech, Amoxycillin Oral Suspension I.P. (Medmoxil 125) manufactured by Laborate Pharmaceuticals, Calcium Carbonate and Vitamin D3 Tablets IP (Calcigiant 500 Tablets) manufactured by Nutra Life Healthcare, Ofloxacin manufactured by Concept Pharmaceutical, Calcium and Vitamin D3 Tablets manufactured by Hanuchem Laboratories, Serratiopeptidase Tablets manufactured by Arnav Research Laboratories.

Furthermore, the list contains, Paracetamol Tablets IP 500 mg (Pyricool 500) manufactured by Alkem Health Science, a unit of Alkem Laboratories Limited, Deferasirox manufactured by Glenmark Lifesciences, Miconazole Nitrate and Fluocinolone Acetonide Ointment (Zole – F) manufactured by Sun Pharmaceuticals and others.

In addition to the above, Telmisartan Tablets 40 mg and Amlodipine 5 mg Tablets IP (Telma AM) belonging batch no 05230355 and Telmisartan Tablets I.P. 40 mg (Telma 40), belonging batch no I8220890 are declared spurious as the actual manufacturer, Glenmark Pharmaceutical (as per label claim) has informed that the impugned batches of the products have not been manufactured by them and that it is a spurious drug.

“Thus, the products are purported to be spurious, however, the same is subject to outcome of further investigation.” the actual manufacturer, Glenmark Pharmaceutical added.

The list came after analysis and tests were conducted by the CDSCO, Drugs Control Departments on 1167 samples. Out of this, 1018 samples were found of standard quality while 58 were declared Not of Standard Quality (NSQ).

A few reasons why the drug samples tested failed were the failure of the assay, failure of the dissolution test, failure of the disintegration test, failure of Uniformity of Dispersion, and the presence of water content and particulate matter etc.

The samples collected were tested in CDL Kolkata, CDTL Hyderabad, CDTL Mumbai, RDTL Chandigarh and RDTL Guwahati.

List of Drugs, Medical Devices, Vaccines and Cosmetics declared as Not of Standard Quality/Spurious/Adulterated/Misbranded for the Month of February– 2024.

Total no. of samples received

– 676

Total number of samples tested

– 1167

Total number of samples declared as of Standard Quality

– 1018

Total number of samples declared as Not of Standard Quality – 58

Total number of samples declared as Spurious

– 02

Total number of samples declared as Misbranded

– NIL

S.N

o

Name of Drugs/medical device/cosmetics

Batch No.

Date of Manufactu re

Date of Expiry

Manufactured By

Reason for failure

Drawn By (From

state/CDS CO Zone)

From (Name of Laboratory)

1

Acepik – P (Aceclofenac and Paracetamol Tablets)

NKT230962A

05/2023

04/2025

Nexkem Biotech Pvt. Ltd., Plot No. 64, HPSIDC, Industrial Area, Baddi, Distt. Solan (H.P.) – 173

205.

Disintegration

Drugs Inspector, Ranchi, Jharkhand

Central Drugs Laboratory, Kolkata

2

Amoxycillin Oral Suspension I.P. (Medmoxil 125)

XMSD-001

03/2023

08/2024

Laborate Pharmaceuticals India Ltd., 51, Indl, Area, Paonta Sahib

(H.P.)

Stability

Drugs Inspector, Ranchi, Jharkhand

Central Drugs Laboratory, Kolkata

3

Calcium Carbonate and Vitamin D3 Tablets IP (Calcigiant 500 Tablets)

NLT-17023

05/2023

04/2025

Nutra Life Healthcare Pvt. Ltd., Plot No. 44-45, Shiv Ganga Industrial Estate,

Lakeshwari, Bhagwanpur, Roorkee, Distt.

Haridwar, Uttarakhand

Assay of Vitamin D3

Drugs Inspector, Ranchi, Jharkhand

Central Drugs Laboratory, Kolkata

4

Ofloxacin Dispersible Tablets IP 100 mg (Oflab 100 DT)

C21O062001

05/2022

04/2024

Concept Pharmaceuticals Ltd., A-28/3 MIDC,

Chikalthana, Aurangabad-431006

Uniformity of Dispersion

Drugs Inspector, Ranchi, Jharkhand

Central Drugs Laboratory, Kolkata

5

Calcium and Vitamin D3 Tablets IP (MAHACAL -500)

KSWAC014

05/2023

04/2025

Hanuchem Laboratories, Plot No. 16-17, Sector – 5, Indl. Area, Parwanoo, Dist.

Solan 173 220 (H.P.)

Assay of Vitamin D3

Drugs Inspector, Ranchi, Jharkhand

Central Drugs Laboratory, Kolkata

6

Serratiopeptidase Tablets (Serrizym Tablet)

AT035M

07/2023

06/2025

Arnav Research Laboratories, 435,

G.I.D.C. 2, Dediyasan, Mehsana,

Gujarat 384002

Assay

Drugs Inspector, Ranchi, Jharkhand

Central Drugs Laboratory, Kolkata

7

Montelukast Sodium and Levocetirizine Hydrochloride Tablet IP (XL-Mont)

TXL012007

11/2022

10/2024

DWD

Pharmaceuticals Ltd., 308/5, Village & Post: Poicha (Rania), Tal Savli, Dist.

Vadodara 391780, Gujarat, India

Desription

Drugs Inspector, Ranchi, Jharkhand

Central Drugs Laboratory, Kolkata

8

Propofol Injection IP 500 mg/50 ml

(Hyprovan 500 Injection)

L3352301A

06/2023

05/2025

Protech Telelinks, Mauza Ogli, Suketi Road, Kala Amb. Dist. Sirmour – 173030 (H.P.)

Assay of Propofol

Drugs Inspector, Bilaspur, Himachal Pradesh

Central Drugs Laboratory, Kolkata

9

Heparin Sodium Injection IP 25000 IU/5ml

22HE16

10/2022

09/2024

SAI Parenterals Limited, D1 & D4, Survey No. 280, Phase-V, IDA, Jeedimetla,

Hyderabad 500 055, Telangana, India

Description, Extractable Volume, Particulate Matter and Assay

Drugs Inspector, Bikaner, Rajasthan

Central Drugs Laboratory, Kolkata

10

Metformin HCl (SR) with Glimepiride & Voglibose Tablets (Metaglim-V2)

T-230859

08/2023

07/2025

Vilin Bio Med Ltd., Unit-II, Khasra No.

85, Madhopur Hazarathpur, Roorkee -247667,

Uttarakhand

Assay of Glimepiride

CDSCO,

Rishikesh

Central Drugs Laboratory, Kolkata

11

Clarithromycin Tablets IP 250 mg

OT-231393

10/2023

09/2025

Orchid Bio-Tech Limited, 65, Peerpura-Delhi Highway, Roorkee- 247667 (U.K.)

Dissolution

CDSCO,

Rishikesh

Central Drugs Laboratory, Kolkata

12

Rabeprazole Sodium & Domperidone Capsules (Deep SR Capsules)

OC-23349

11/2023

10/2025

Orchid Bio-Tech Limited, 65, Peerpura-Delhi

Highway, Roorkee – 247667 (U.K.)

Dissolution of Rabeprazole & Domperidone

CDSCO,

Rishikesh

Central Drugs Laboratory, Kolkata

13

Glimepiride & Meftormin Hydrochloride Prolonged Release Tablets IP (Glimsid-

2MF)

T-231020

10/2023

09/2025

Vilin Bio Med Ltd., Unit-II, Khasra No.85, Madhopur, Hazarathpur, Roorkee-247667,

Uttarakhand.

Dissolution & Assay of Glimepiride

CDSCO,

Rishikesh

Central Drugs Laboratory, Kolkata

14

Liquid Formaldehyde 40% w/v (Formallin)

FS-228A

08/2022

07/2025

Pharm Asia Drug, 20-21, Panchal Compound, Survey

No. 78/1, PH No. 17,

New 45, Gram Lasudia Mori, Indore

– 452 010 (M.P.)

Methyl Alcohol & Assay of Formaldehyde 40%w/v

CDSCO,

North Zone

Central Drugs Laboratory, Kolkata

15

Piroxicam Capsules IP (Piroxicam-20)

KCC-03

11/2023

10/2025

SGS Pharmaceutical (P) Ltd., E-13/1,

Kavi Nagar Indl. Area, Sector – 17, Ghaziabad 201002

(U.P.)

Water content

CDSCO,

North Zone

Central Drugs Laboratory, Kolkata

16

Hydrogen Peroxide Topical Solution IP 6% w/v (20 Volume)

HP23-021

02/2023

01/2025

Pharm Asia Drug, 20-21, Panchal Compound, Survey

No. 78/1, PH No. 17,

New 45, Gram Lasudia Mori, Indore

– 452 010 (M.P.)

Identification, Acidity, Non-volatile matter and Assay

(Spurious)

CDSCO,

North Zone

Central Drugs Laboratory, Kolkata

17

L-Asparaginase 10000 IU (L-ASGEN)

BASL2205Y A

03/2022

02/2024

Beta Drugs Ltd., Kharuni Lodhimajra Road, Vill. Nandpur, Baddi, Dist. Solan, Himachal Pradesh

173205

Particulate Matter (subvisible)

O/o. The Drugs Inspector, Cuttack, Odisha.

Central Drugs Laboratory, Kolkata

18

Amikacin Injection IP 500 mg (Amikatas 500 mg)

RV3044

08/2023

07/2025

Ronam Healthcare Pvt. Ltd. Village- Kalujhanda, Tehsil- Baddi, Distt. Slolan (H.P.) 174103

Description & Particulate Matter

O/o. The Drugs Inspector, Cuttack, Odisha.

Central Drugs Laboratory, Kolkata

19

Neostigmine Injection IP 0.5 mg/ml

V23034

01/02/2023

31/01/2025

Vital Healthcare Pvt. Ltd., Plot No. H10 and H10/1, MIDC Satpur, Nashik.

pH and Assay of Neostigmine

CDSCO,

West Zone, Mumbai

Central Drugs Laboratory, Kolkata

20

Tranexamic Acid Injection I.P. (Tranexica)

SAI-14764

03/2022

02/2024

Sunvet Healthcare, Vill. Shambhuwala, Paonta Road, Distt. Sirmour (H.P.) –

173001

pH

DCA,

Vijayawada

, Andhra Pradesh

Central Drugs Laboratory, Kolkata

21

Paracetamol Tablets IP 500 mg (Pyricool 500)

23444042

11/2023

10/2026

Alkem Health Science, A unit of Alkem Laboratories Limited, Unit – 2,

Samardung, Karek

Dissolution

CDSCO,

East Zone, Kolkata

Central Drugs Laboratory, Kolkata

Block, P.O. Namthan, Dist. Namchi, Sikkim –

737137

22

Ciprofloxacin Hydrochloride Tablets IP 500 mg

2331044

07/2023

06/2026

Aurio Pharma Laboratories Pvt. Ltd., 26/1/1, S.H.K.B

Sarani (Jawpur Road), Dumdum,

Kolkata- 700 074

Dissolution

CDSCO,

East Zone, Kolkata

Central Drugs Laboratory, Kolkata

23

Oseltamivir Oral Suspension I.P. 12 mg

URDP1153

05/2023

10/2024

Unicure India Ltd., Plot No. 46(B) / 49B,

Vill. Raipur, Bhagwanpur, Roorkee, Distt.

Haridwar, Uttarakhand

Description

CDSCO,

East Zone, Kolkata

Central Drugs Laboratory, Kolkata

24

Ambroxol,Guaiphenes in & Terbutaline Syrup (Bromex Expectorant)

BXE064

01/09/2023

31/05/2026

Hygeia Pharmaceuticals MFG (P) Ltd., 608,

Dwarir Road, Dhamaitala Dakshin Jagaddal, Pin – 700

151

Assay of Ambroxol Hydrochloride and Terbutaline Sulphate

CDSCO,

East Zone, Kolkata

Central Drugs Laboratory, Kolkata

25

Paracetamol, Phenylephrine Hydrochloride, Chlorpheniramine Maleate, Sodium Citrate and Menthol

Syrup (SUNGESIC-C)

002

01/09/2023

31/08/2025

Sunny Industries Private Limited, 23/3/1B, R.N.

Nandan Lane, Kolkata 700 025

Description & Assay of Paracetamol

CDSCO,

East Zone, Kolkata

Central Drugs Laboratory, Kolkata

26

Deferasirox

82231480

02/07/2023

01/07/2027

Glenmark Lifesciences Ltd., Plot No. Z-103/I, Sez Phase II, Dahej, Dist.

Bharuch – 392130, Gujarat, India.

4 Hydrazino benzoic acid

CDSCO,

Ahmedabad

Central Drugs Laboratory, Kolkata

27

Miconazole Nitrate and Fluocinolone Acetonide Ointment (Zole – F)

SXE1800A

08/2023

07/2026

Sun Pharmaceuticals Ind. Ltd., Kh. No. 1335-1340, Near

EPIP- I, Vill- Bhatoli

Kalan, Baddi, Distt. Solan, H.P. 173205

Assay

CDSCO,

Ahmedabad

Central Drugs Laboratory, Kolkata

28

Trihexyphenidyl Hydrochloride Tablets IP 2 mg (Ridyl)

AR-132

06/2023

05/2025

Apex Formulations Pvt. Ltd., 1276,

Rajpur, Ahmedabad- Mehsana Highway, Dist. Mehsana,

Gujarat.

Assay

CDSCO,

Ahmedabad

Central Drugs Laboratory, Kolkata

29

Levosalbutamol Sulphate, Ambroxol Hydrochloride, Guaiphenesin and Menthol Syrup 60 ml Syrup (HISTARED- LS)

L23K015

11/2023

10/2025

Fanal Pharmaceuticals LLP, 67, Surbhi Radhe Industrial Zone, Survey No. 251, At. Khambha,

360311, Gujarat, India

Description & Assay of Levosalbutamol

CDSCO,

Ahmedabad

Central Drugs Laboratory, Kolkata

30

TERBUTALINE SULPHATE, BROMHEXINE HCl & GUAIPHENESIN SYRUP (NEFDYL-X)

WHL-01715

Nov-2023

Oct-2025

Warner Hindusthan Pvt. Ltd.,. 24-85/7, Sy.No.548 & 551,

Laxmi Narayana Nagar Colony, New

IDA, Uppal, Hyderabad-39 (TS)

Assay of Bromhexine Hydrochloride

CDSCO

Hyderabad

CDTL,

Hyderabad

31

BROMHEXINE HYDROCHLORIDE

SYRUP 4mg/5ml

31413

01-Aug-

2023

31-Jul-2025

Zenith Drugs Pvt.

Ltd., 72/5, Muradpura (Orangpura) Dhar Road, Near Kalaria, Indore 453001 (MP) India

pH and Assay

CDSCO,

Sub Zone, Indore

CDTL,

Hyderabad

32

POVIDONE-IODINE SOLUTION BP (VIDON)

EVO310

01-Jun-

2023

31-May-

2026

US PHARMA (I) PVT.LTD

Plot No. 4, Gut No. 66, H.No. 827-830,

Khupi Village, Near Kudus, Tal. Wada, Dist. Palghar, 421312, Maharashtra,

India.

pH

CDSCO,

West Zone, Mumbai

CDTL,

Hyderabad

33

Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride & Chlorpheniramine

Maleate Syrup (Zist- D)

HRL-070

Oct-23

Sep-25

Household Remedies Pvt. Ltd., Plot No.6/35, Dewan And Sons Aliyali,

Palghar- 401 404.

Microbial Limit test

CDSCO,

West Zone, Mumbai

CDTL,

Mumbai

34

Pantoprazole Gastro- resistant Tablets IP (Pantojohn – 20)

T-2210131

Oct-22

Sep-25

Johnlee Pharmaceuticals Pvt Ltd., By Aagya Biotech Pvt. Ltd., 1.5, Manglour- saharanpur road, Manglour- 247656,

Roorkee, Haridwar.

Dissolution in buffer stage

CDSCO,

West Zone, Mumbai

CDTL,

Mumbai

35

Atorvastatin and Clopidogrel Capsules (10mg/75mg)

MC221173

Dec-2022

Nov-2024

Mascot Health Series Pvt. Lt., Plot No. 79,80,Sector-6A, IIE,

Sidcul, Haridwar- 249403

Dissolution of Atorvastatin Calcium calculated as Atorvastatin

CDSCO,

North Zone Ghaziabad

RDTL,

Chandigarh

36

Moxonidine Tablets BP (0.3 mg)

MXDY0005

Jun-2022

May-2025

MICRO LABS LIMITED UNIT-III, R.S.No. 63/ 3 & 4,

Thiruvander Koil, Puducherry-605102

Dissolution

CDSCO,

North Zone Ghaziabad

RDTL,

Chandigarh

37

Calcium Carbonate, Vitamin D3 and L- Lysine Suspension (Oscaid Suspension)

RL22070

Aug-2022

Jul-2024

RACHIL PHARMA.., 18-19,

Phase-1, Ind.Area, Sansarpur Terrace, Distt : Kangra (HP)-

176501

Description, Identification and Assay of Vitamin D3

O/o CMO Bilaspur District- Bilaspur H.P.-

174001

RDTL,

Chandigarh

38

Cefodoxime Proxetil and Potassium Clavulanate Tablets

MBT-22012

Jun-2022

Sep-2023

Magnatek Enterprises, Plot No. 74 C (II) HPSIDC

Ind. Area Baddi, Distt. Solan (H.P.) 1732025

Assay of Potassium Clavulanate Diluted calculated as Clavulanic Acid

O/o State Drugs Controller,

H.Q. Baddi, Distt.

Solan, HP- 173205

RDTL,

Chandigarh

39

Ofloxacin and Ornidazole Tablets IP (Normal -OZ TABLETS)

122257

Dec-2022

Nov-2024

Biologics Inc., Suketi Road, Kala-Amb, Distt. Sirmour (H.P.)- 173030

Dissolution of Ofloxacin and Ornidazole

State FDA Qatilgah Kargil- 194103 (UT

Ladakh)

RDTL,

Chandigarh

40

Cefuroxime Axetil Tablets IP 500 mg

JAK-20

May-2023

Arp-2025

Agron Remedies Pvt. Ltd., Sarverkhera, Moradabad Road, Kashipur-244713

(Uttarakhand)

Dissolution and Assay of Cefuroxime Axetil calculated as Cefuroxime

CDSCO

Sub-Zone, Jammu

RDTL,

Chandigarh

41

Ambroxol, Terbutaline Sulphate, Guaiphenesin and Menthol Syrup (Tricodex A Syrup)

SRLK230054

Nov-2023

Oct-2025

SYSTOLE REMEDIES PVT.

LTD. Vill. Ogli, Kala Amb, Teh. Nahan, Distt. Sirmour (H.P.)-

173030

Assay of Terbutaline Sulphate

CDSCO ,

Baddi

RDTL,

Chandigarh

42

Ambroxol hydrochloride, Terbutaline Sulphate, Guaiphenesin and Menthol Syrup

(Bronter SYRUP)

NARL-0038

Nov-2023

Oct-2025

M Sea Pharmaceuticals (P) Ltd., Surajpur, Paonta Sahib, Sirmour Himachal

Pradesh-173001

Assay of Menthol

CDSCO ,

Baddi

RDTL,

Chandigarh

43

Ambroxol Hydrochloride, Levosalbutamol and Guaiphenesin Syrup (Saivent-LX Syrup)

MAG-S-1972

Oct-2023

Sep-2025

Magma Allianz Laboratories Ltd., Vill. Guruwala, P.O. Bhagani Sahib, Teh. Paonta Sahib, Distt.

Sirmour (H.P.)- 173025

Assay of Ambroxol Hydrochloride and Levosalbutamol Sulphate calculated as Levosalbutamol

CDSCO

Baddi

RDTL,

Chandigarh

44

Ambroxol Hydrochloride, Levosalbutamol Sulphate and Guaiphenesin Syrup (KOFVON LS Syrup)

OL-032309

Mar-2023

Feb-2025

Sickcure Pharmaceuticals, Plot No. 52A, Industiral Area, Gondpur, Tehsil-Paonta Sahib, Distt. Sirmour (H.P.)

173025

Ethylene Glycol (EG) is exceeding the permissible limit

CDSCO

Baddi

RDTL,

Chandigarh

45

Ambroxol Hydrochloride, Terbutaline Sulphate, Guaiphenesin and Menthol Syrup (AVTUS-TG SYRUP)

BL-36

Jul-2023

Jun-2025

Boffin Biotech Pvt. Ltd., Vill. Behral, Paonta Sahib, Distt. Sirmour-173025 (H.P.)

Assay of Menthol

CDSCO

Baddi

RDTL,

Chandigarh

46

Chlorpheniramine Maleate, Dextromethorphan Hydrobromide and Phenylephrine Hydrochloride Syrup

(Expotus-D Syrup)

LSF-B0075

Apr-2023

Mar-2025

Spen Formulations Pvt. Ltd., Plot No- 123, Industrial Area, Mehatpur, Distt.

UNA-174315 (H.P.)

Assay of Chlorpheniramine Maleate, Dextromethorphan Hydrobromide and Phenylephrine

Hydrochloride

CDSCO

Baddi

RDTL,

Chandigarh

47

Dextromethorphan Hyhdrobromide, Phenylephrine Hydrochloride and Chlorpheniramine Maleate Syrup

(ROYCOF-DX SYRUP)

GL2301001

Jan-2023

Dec-2024

Roseate Medicare, Village Anji, PO Barog, Distt. Solan, 173211 (H.P.) INDIA

Identification and Assay of Chlorpheniramine Maleate and Assay of Dextromethorphan Hydrobromide

CDSCO

Baddi

RDTL,

Chandigarh

48

Terbutaline Sulphate, Guaiphenesin, Ambroxol Hydrochloride and Menthol Syrup (Xpert- S Syrup)

6530

Feb-2023

Jan-2025

ESTRA PHARMACEUTICA

LS, Fatehgarh Churian Road, Amritsar Br.

Assay of Ambroxol Hydrochloride and Menthol

CDSCO

Baddi

RDTL,

Chandigarh

49

LEVOCETIRIZINE HYDROCHLORIDE & MONTELUKAST SODIUM TABLETS

I.P. (Cetliv-M)

MDHMT-436

Mar-2023

Feb-2025

M Sea Pharmaceuticals (P) Ltd. (A GMP ISO 9001: 2015 CERTIFIED CO.,

Surajpur, Paonta Sahib, Sirmour

(H.P.)- 173001

Dissolution of Montelukast

Assistant Director (Food & Drugs) Mizoram

RDTL,

Guwahati

50

Levocetirizine Dihydrochloride and Montelukast Sodium Tablets IP

23112703

Mar-2023

Feb-2025

MERCURY LABORATORIES LIMITED., Unit

No.2, Halol Baroda Road, Village: Jarod. Tal: Waghodia, Dist:

Vadodara- 391510

Dissolution of Montelukast

Inspector of Drugs, Assam

RDTL,

Guwahati

51

DICLOFENAC SODIUM INJECTION I.P.

75mg/3ml

I213109

Jul-2023

Jun-2025

ANG Lifesciences India Ltd., Village Malkumajra, Nalagarh Road, Baddi, Distt. Solan- 173205 (H.P.)

Description

Inspector of Drugs, Assam

RDTL,

Guwahati

52

Montelukast Sodium and Levocetirizine Hydrochloride Tablets IP (Montas- L)

MAT22030

Jun-2022

May-2024

Tirupati Medicare Limited, Nahan Road, Paonta Sahib, Dist. Sirmour, Himachal Pradesh –

173 025, India.

Dissolution of Montelukast

Inspector of Drugs, Sikkim

RDTL,

Guwahati

53

Pheniramine Maleate Tablet I.P. (APVIL)

RT220422

May-2022

Apr-2025

Ridley Life Science Pvt. Ltd.,, D-1651, DSIDC, Indl.

Complex, Narela, Delhi- 110040

Description

Inspector of Drugs, Assam

RDTL,

Guwahati

54

Pheniramine Maleate Tablet IP (APVIL)

RT220512

Jun-2022

May-2025

RIDLEY LIFE SCIENCE PVT. LTD., D-1651, DSIDC Indl.

Complex, Narela, Delhi-110040

Description

Inspector of Drugs, Assam

RDTL,

Guwahati

55

Levocetirizine Hydrochloride & Montelukast Sodium

IP Tablets (Raremont- LC)

TSF-B1689

Apr-2023

Mar-2025

Spen Formulations Pvt. Ltd., Plot No- 123, Industrial Area, Mehatpur, Distt.

UNA- 174315 (H.P.)

Dissolution and Assay of Montelukast

Inspector of Drugs, Assam

RDTL,

Guwahati

56

Serratiopeptidase Tablets IP 10 mg (Serrarid-10)

RT220358

Apr-2022

Mar-2024

RIDLEY LIFE SCIENCE PVT. LTD, D-1651, DSIDC, Indl.

Complex, Narela, Delhi-110040

Disintegration & Description

Inspector of Drugs, Meghalaya

RDTL,

Guwahati

S.No

Name of Drugs/medical device/cosmetics

Batch No.

Date of Manuf

acture

Date of Expiry

Manufacture d By

Reason for failure

Drawn By (From state/CDS

CO Zone)

From (Name of Laboratory)

Remarks

57

Telmisartan Tablets 40 mg and Amlodipine 5 mg Tablets IP (Telma AM)

05230355

03/202

3

02/2026

Glenmark Pharmaceutica ls Ltd., Village Kishanpura, Baddi- Nalagarh Road, Tehsil Baddi, Distt. Solan (H.P.)

Assay & Dissolution of Telmisartan & Amlodipine

CDSCO,

North Zone

Central Drugs Laboratory, Kolkata

The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. Thus, the product is purported to be spurious, however, the same is

subject to outcome of further investigation.

58

Telmisartan Tablets I.P. 40 mg (Telma 40)

I8220890

12/202

2

11/2025

Glenmark Pharmaceutica ls Ltd., Samlik Marchak, Industrial Growth Centre, East Sikkim, Sikkim – 737135

Dissolution

CDSCO,

North Zone

Central Drugs Laboratory, Kolkata

The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. Thus, the product is purported to be spurious, however, the same is subject to outcome of

further investigation.

Also Read: AstraZeneca India bags dual CDSCO nod for Trastuzumab deruxtecan

To view the official notice, click the link below:

https://medicaldialogues.in/pdf_upload/feb2024-alert-235330.pdf

Powered by WPeMatico

Orthopedic Surgeon directed to pay compensation to patient for medical negligence

The Urbal II Additional District Consumer Disputes Redressal Commission, Bengaluru recently directed an Orthopaedic Surgeon to pay around Rs 4 lakh compensation to a patient for medical negligence while conducting Total Knee Replacement Surgery.

After the surgery, the patient had to suffer unbearable pain and had to seek treatment at another hospital. The Consumer Court held the doctor liable after noting that the Karnataka Medical Council (KMC) opined that “good quality of implant was not used” resulting in infection in the wound. KMC had also observed that the patient was not managed by proper follow-up and medication and for this, the Council held the treating surgeon responsible.

For more information, click on the link below:

Powered by WPeMatico

Security deposit for super speciality counselling refunded to candidates, informs MCC

Through a recent notice, the Medical Counseling Committee (MCC) has informed that the security deposit for super speciality counselling has been refunded to the concerned candidates.

As per the notice, “It is for the information of all the candidates participated in SS Counselling 2023 that as per the eligibility conditions mentioned in the SS Information Bulletin for Security deposit refund, the refund of security deposit has been done on 29.03.2024”.

For more information, click on the link below:
MCC Issues Notice On Security Deposit Refund To NEET SS 2023 Candidates, Details

Powered by WPeMatico